Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.54 |
| ▸ | KDR | P35968 | 13/20 | 0.54 |
| ▸ | CSK | P41240 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168041 | 0.96 | SRC (0.51) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4024733 | 0.92 | SRC (0.57) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4023466 | 0.91 | SRC (0.54) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4029134 | 0.91 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4030606 | 0.91 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4030035 | 0.89 | SRC (0.68) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4023194 | 0.87 | SRC (0.53) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4025613 | 0.86 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4026192 | 0.85 | SRC (0.62) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4028028 | 0.84 | SRC (0.56) | SRCKDRCSKTEKEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | SRC 1917/4885KDR 2563/4885CSK 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.